Fluoroquinolone-Based Regimens for Drug-Resistant Tuberculosis

Core Role of Fluoroquinolones in MDR-TB Treatment

The Centers for Disease Control and Prevention recommends that fluoroquinolones, specifically later-generation agents like levofloxacin or moxifloxacin, are essential core components of treatment regimens for multidrug-resistant tuberculosis (MDR-TB) and should be included in virtually all MDR-TB treatment plans unless documented resistance exists 1, 2
The World Health Organization classifies fluoroquinolones as Group A priority drugs alongside bedaquiline and linezolid for MDR-TB therapy 3
Later-generation fluoroquinolones (levofloxacin or moxifloxacin) are strongly preferred over older agents like ciprofloxacin or ofloxacin due to superior bactericidal activity and lower relapse rates 3
Most MDR-TB regimens combine a fluoroquinolone with an aminoglycoside (streptomycin, kanamycin, amikacin) or capreomycin 1, 2

The American Thoracic Society recommends that for eligible MDR/RR-TB patients, the 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) represents the preferred treatment option 4
Eligibility criteria for the BPaLM regimen include no previous exposure to second-line TB drugs for >1 month, no fluoroquinolone resistance on drug susceptibility testing, absence of extensive pulmonary disease, and not pregnant 3, 4
The BPaLM regimen composition includes bedaquiline (daily for 2 weeks, then thrice weekly for 22 weeks), pretomanid (daily), linezolid (daily), and moxifloxacin (daily) 4, 6

The European Respiratory Society recommends that when the shorter regimen is contraindicated, construct a longer regimen using at least 5 effective drugs, prioritizing Group A agents (fluoroquinolone, bedaquiline, linezolid) 3, 4
The treatment duration for longer individualized regimens is 24 months after culture conversion for HIV-positive patients with MDR-TB, and 20-24 months total duration for most MDR-TB cases 1, 2, 5

The Infectious Diseases Society of America recommends adding a later-generation fluoroquinolone (levofloxacin or moxifloxacin) to a 6-month regimen of daily rifampin, ethambutol, and pyrazinamide for isoniazid-resistant, rifampin-susceptible TB 7, 6, 5

The Centers for Disease Control and Prevention recommends never using ciprofloxacin or older fluoroquinolones for TB treatment due to higher relapse rates, longer time to sputum culture conversion, and treatment failure 7
Cross-resistance between ofloxacin and moxifloxacin is incomplete, and drug susceptibility testing for fluoroquinolones should be obtained before initiating treatment 7, 3

The World Health Organization recommends implementing active drug safety monitoring (aDSM) for all MDR-TB patients, particularly monitoring for QTc prolongation, tendon rupture and arthropathy, peripheral neuropathy, and hepatotoxicity 3, 4, 5, 6, 7

For HIV co-infected patients, the American Thoracic Society recommends extending treatment to at least 9 months and for at least 6 months beyond documented culture conversion, and carefully managing drug interactions between antiretrovirals and fluoroquinolones 4, 6
For pregnant women, the Centers for Disease Control and Prevention recommends that fluoroquinolones can be used when benefits outweigh risks in MDR-TB, and avoiding aminoglycosides entirely due to fetal toxicity 1, 2, 6, 5

The European Respiratory Society recommends monthly sputum cultures to monitor treatment response, and discussing all MDR-TB cases at a TB consilium (local, regional, or national expert panel) for treatment optimization 4, 3